CIML NK Cells With Venetoclax for AML
Phase 1 Recruiting
10 enrolled
NK4AML
Phase 1/2 Terminated
9 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
ABCD-NK
Phase 1/2 Recruiting
68 enrolled
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Phase 1 Recruiting
15 enrolled
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Phase 1 Suspended
12 enrolled
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Phase 1 Terminated
16 enrolled
The Maintenance Treatment of "ITIVA" in AML Patients
Phase NA Recruiting
130 enrolled
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1/2 Terminated
89 enrolled 17 charts
FT516 in Subjects With Advanced Hematologic Malignancies
Phase 1 Terminated
72 enrolled
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
Phase 2 Withdrawn
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Phase 2 Withdrawn
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
Phase 1 Completed
10 enrolled
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Phase 2 Completed
7 enrolled
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Phase 2 Completed
25 enrolled 12 charts
Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia
Phase 2 Terminated
18 enrolled 5 charts
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase 2 Completed
21 enrolled 10 charts
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
Phase 1/2 Completed
50 enrolled 13 charts
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Phase 2 Terminated
16 enrolled 19 charts
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Phase 2 Terminated
2 enrolled 13 charts
T-Cell Depleted Double UCB for Refractory AML
Phase 2 Terminated
3 enrolled 9 charts
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Phase 4 Completed
84 enrolled
Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
30 enrolled 9 charts
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Phase 2 Terminated
12 enrolled 12 charts
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase 1/2 Completed
37 enrolled
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Completed
15 enrolled
Natural Killer (NK) Cell Transplantation for AML
Phase NA Completed
49 enrolled 17 charts
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors
Phase 1 Completed
22 enrolled